Please login to the form below
Reyvow
This page shows the latest Reyvow news and features for those working in and with pharma, biotech and healthcare.
Biohaven gets FDA approval for migraine drug Nurtec ODT
Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T. ... Reyvow was approved by the FDA last October but only launched a month ago, as it needed a scheduling review by the
Latest news
-
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Enters increasingly competitive market. Eli Lilly has launched its new acute migraine medicine Reyvow, following the successful completion of a Drug Enforcement Administration review. . ... Lilly said it will offer a ‘Reyvow Savings Card’ for
-
Allergan gets FDA nod for first oral CGRP drug for migraine
Ubrelvy’s closest CGRP rival is Biohaven’s late-stage candidate rimegepant, which could join it on the market next year, and it also faces competition from Lilly’s Reyvow (lasmiditan),
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed in the acute treatment setting, rimegepant will also have to beat competitors like Reyvow and Ubrelvy, both of which are also oral drugs with very attractive profiles. ... Eli Lilly/Dong Pharmaceuticals’ 5-HT1f agonist Reyvow was approved in
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- COVID-19 vaccine developers respond to new strain
- Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- Live Webinar: COVID-19 Has Changed Live Events Forever!
- New hire and promotions announced at Evoke KYNE
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Lucid Group bolster its talent with a further twelve new starters for 2021
- UK pharmacies to begin administering COVID-19 vaccinations
- PHE study finds people who have had COVID-19 can still transmit the virus
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- AstraZeneca’s focus on diagnosing and managing chronic kidney disease
- People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
- Delphi Technique Virtual Co-creation: A Customer Story
- How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
- Three ways AI will change healthcare in the next decade
- Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...
Quick links
Infographics
